SCHEMBL2635582

SCHEMBL2635582

COC(=O)c1cc(O)c2c(Cl)cc(Cl)cc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.51
KDM4E B2RXH2 3/20 0.51
XDH P47989 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
POLB P06746 1/20 0.51
GAA P10253 1/20 0.51
NFKB1 P19838 1/20 0.51
GFER P55789 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
FUT7 Q11130 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
PTPN11 Q06124 3/20 0.49
CNR2 P34972 2/20 0.46
CA12 O43570 2/20 0.45
CA1 P00915 2/20 0.45
CA2 P00918 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
CA14 Q9ULX7 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14743698 0.83 ALDH1A1 (0.44) LMNAKDM4EXDHTDP1POLB
SCHEMBL14743299 0.82 ALDH1A1 (0.42) LMNAKDM4EXDHTDP1POLB
SCHEMBL2635663 0.80 TPMT (0.50) LMNAKDM4ETDP1POLBGAA
SCHEMBL14744278 0.80 ALDH1A1 (0.57) KDM4EPTPN11CA12CA1CA2
SCHEMBL2635505 0.77 KMT2A (0.43) TDP1GAAALDH1A1MAPTKMT2A
SCHEMBL14743076 0.76 ALDH1A1 (0.38) KDM4ETDP1PTPN11HPGDALDH1A1
SCHEMBL2635943 0.76 TDP1 (0.49) KDM4ETDP1POLBHPGDALDH1A1
SCHEMBL2635722 0.76 LMNA (0.38) LMNAKDM4ETDP1PTPN11HPGD
SCHEMBL14743979 0.76 TSHR (0.42) LMNAL3MBTL1HPGDALDH1A1MAPT
SCHEMBL14742913 0.76 RAB9A (0.49) KDM4EL3MBTL1HPGDALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013030358-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2013-03-07 WO disclosed
US-20120220577-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO KGAA 2012-08-30 US disclosed
EP-2438037-A1 GLYCINE B ANTAGONISTS Merz Pharma GmbH & Co. KGaA (DE) 2012-04-11 EP disclosed
WO-2010139481-A1 GLYCINE B ANTAGONISTS MERZ PHARMA GMBH & CO. KGAA (DE) 2010-12-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120220577-A1 GLYCINE B ANTAGONISTS GLRB, GRIN2B, GLRA2 LMNA 1894/4885KDM4E 4569/4885XDH 995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.